Jeanny B Aragon-Ching

List of Publications by Year
in descending order

Version: 2024-02-01

152 papers	4,257 citations	172207 29 h-index	118652 62 g-index
153 all docs	153 docs citations	153 times ranked	5952 citing authors

#	Article	IF	Citations
1	Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine, 2020, 383, 1218-1230.	13.9	802
2	American Cancer Society prostate cancer survivorship care guidelines. Ca-A Cancer Journal for Clinicians, 2014, 64, 225-249.	157.7	324
3	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2017, 35, 1341-1367.	0.8	318
4	Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel. Clinical Cancer Research, 2008, 14, 4200-4205.	3.2	204
5	A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer. Clinical Cancer Research, 2008, 14, 209-214.	3.2	174
6	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet, The, 2017, 390, 2266-2277.	6.3	153
7	Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy. Clinical Cancer Research, 2009, 15, 1411-1416.	3.2	135
8	Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Frontiers in Bioscience - Landmark, 2007, 12, 4957.	3.0	130
9	ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel. Clinical Cancer Research, 2008, 14, 4543-4549.	3.2	127
10	Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents. Cancer Investigation, 2009, 27, 221-226.	0.6	115
11	Final analysis of a phase II trial using sorafenib for metastatic castrationâ€resistant prostate cancer. BJU International, 2009, 103, 1636-1640.	1.3	112
12	CNS Metastasis: An Old Problem in a New Guise. Clinical Cancer Research, 2007, 13, 1644-1647.	3.2	89
13	Role of chemotherapy in prostate cancer. Asian Journal of Andrology, 2018, 20, 221.	0.8	85
14	Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. Journal of Clinical Oncology, 2016, 34, 1500-1509.	0.8	72
15	Thalidomide Analogues as Anticancer Drugs. Recent Patents on Anti-Cancer Drug Discovery, 2007, 2, 167-174.	0.8	69
16	Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.. Journal of Clinical Oncology, 2020, 38, LBA1-LBA1.	0.8	64
17	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2020, 21, 105-120.	5.1	61
18	VEGF Inhibitors and Prostate Cancer Therapy. Current Molecular Pharmacology, 2009, 2, 161-168.	0.7	59

#	Article	IF	Citations
19	Vitamin D in prostate cancer. Asian Journal of Andrology, 2018, 20, 244.	0.8	59
20	Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer. Journal of Clinical Pharmacology, 2009, 49, 650-660.	1.0	52
21	A Double-Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo for Androgen Dependent Prostate Cancer Treated With Intermittent Androgen Ablation. Journal of Urology, 2009, 181, 1104-1113.	0.2	41
22	Role of immunotherapy in bladder cancer. Cancer Treatment and Research Communications, 2021, 26, 100296.	0.7	41
23	The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Therapeutic Advances in Medical Oncology, 2013, 5, 25-40.	1.4	40
24	Kinetics of Serum Androgen Normalization and Factors Associated With Testosterone Reserve After Limited Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer. Journal of Urology, 2008, 180, 1432-1437.	0.2	36
25	Multidisciplinary Management of Muscle-Invasive Bladder Cancer: Current Challenges and Future Directions. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 307-318.	1.8	35
26	Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer. Clinical Medicine Insights: Oncology, 2016, 10s1, CMO.S34535.	0.6	34
27	Characterization of Differences Between Prostate Cancer Patients Presenting With De Novo Versus Primary Progressive Metastatic Disease. Clinical Genitourinary Cancer, 2018, 16, 85-89.	0.9	34
28	Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms. Prostate Cancer, 2013, 2013, 1-10.	0.4	33
29	The Role of Angiogenesis Inhibitors in Prostate Cancer. Cancer Journal (Sudbury, Mass), 2008, 14, 20-25.	1.0	31
30	The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer. Clinical Medicine Insights: Oncology, 2019, 13, 117955491983392.	0.6	30
31	The Evolution of Prostate Cancer Therapy: Targeting the Androgen Receptor. Frontiers in Oncology, 2014, 4, 295.	1.3	28
32	Angiogenesis Inhibition in Prostate Cancer: Current Uses and Future Promises. Journal of Oncology, 2010, 2010, 1-7.	0.6	27
33	Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer. Clinical Medicine Insights: Oncology, 2016, 10, 11.	0.6	27
34	Acute aortic dissection in a hypertensive patient with prostate cancer undergoing chemotherapy containing bevacizumab. Acta OncolÃ³gica, 2008, 47, 1600-1601.	0.8	24
35	Phase II Study of Satraplatin and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Pharmacogenetic Assessment of Outcome and Toxicity. Clinical Genitourinary Cancer, 2013, 11, 229-237.	0.9	23
36	Zoledronic acid for the treatment of prostate cancer. Expert Opinion on Pharmacotherapy, 2019, 20, 657-666.	0.9	23

#	Article	IF	Citations
37	Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial.. Journal of Clinical Oncology, 2022, 40, 487-487.	0.8	23
38	Anti-angiogenesis approach to genitourinary cancer treatment. Update on Cancer Therapeutics, 2009, 3, 182-188.	0.9	22
39	Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide. Clinical Medicine Insights: Oncology, 2013, 7, CMO.S11670.	0.6	22
40	From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Review of Vaccines, 2011, 10, 743-753.	2.0	20
41	Advances and Controversies With Checkpoint Inhibitors in Bladder Cancer. Clinical Medicine Insights: Oncology, 2021, 15, 117955492110449.	0.6	18
42	Unravelling the role of denosumab in prostate cancer. Lancet, The, 2011, 377, 785-786.	6.3	17
43	Mucosa-Associated Lymphoma Tissue of the Dura Presenting as Meningioma. Southern Medical Journal, 2010, 103, 950-952.	0.3	15
44	Treatment of Adult Soft Tissue Sarcoma: Old Concepts, New Insights, and Potential for Drug Discovery. Cancer Investigation, 2012, 30, 300-308.	0.6	13
45	Targeted therapies in the treatment of urothelial cancers. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 465-472.	0.8	13
46	Angiogenesis inhibitors in prostate cancer therapy. Discovery Medicine, 2010, 10, 521-30.	0.5	13
47	Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?. Cancer Therapy, 2007, 5A, 151-160.	2.9	12
48	Complete Response to EPOCH in a Patient With HIV and Extracavitary Primary Effusion Lymphoma Involving the Colon: A Case Report and Review of Literature. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 144-147.	0.2	11
49	Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer. Clinical Genitourinary Cancer, 2015, 13, e341-e345.	0.9	11
50	A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100). Annals of Oncology, 2016, 27, vi292.	0.6	11
51	Challenges and advances in the diagnosis, biology, and treatment of urothelial upper tract and bladder carcinomas. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 462-464.	0.8	11
52	Radium-223 for the treatment of castration-resistant prostate cancer. OncoTargets and Therapy, 2015, 8, 1103.	1.0	10
53	The immunotherapy revolution in genitourinary malignancies. Immunotherapy, 2020, 12, 819-831.	1.0	10
54	Advances with androgen deprivation therapy for prostate cancer. Expert Opinion on Pharmacotherapy, 2022, 23, 1015-1033.	0.9	10

#	Article	IF	Citations
55	Novel androgen deprivation therapy (ADT) in the treatment of advanced prostate cancer. Drug Discovery Today: Therapeutic Strategies, 2010, 7, 31-35.	0.5	9
56	A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma. Vaccines, 2021, 9, 919.	2.1	9
57	Osteonecrosis of the Jaw and the Use of Antiangiogenic Agents: Just an Association?. Oncologist, 2008, 13, 1314-1314.	1.9	8
58	Positron emission tomography findings in clinical mimics of lymphoma. Annals of the New York Academy of Sciences, 2011, 1228, 19-28.	1.8	8
59	Primary Diffuse Large B-Cell Lymphoma of the Ureter in a Patient With HIV: A Case Report and Review of Literature. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 324-326.	0.2	8
60	Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises. Future Oncology, 2016, 12, 2049-2058.	1.1	8
61	Epithelioid Angiosarcoma of the Bladder: A Case Report and Review of the Literature. Clinical Genitourinary Cancer, 2018, 16, e1091-e1095.	0.9	8
62	Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.. Journal of Clinical Oncology, 2021, 39, 4520-4520.	0.8	8
63	Protein kinase inhibitors for the treatment of prostate cancer. Expert Opinion on Pharmacotherapy, 2021, 22, 1889-1899.	0.9	8
64	A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia. Expert Opinion on Investigational Drugs, 2015, 24, 1059-1073.	1.9	7
65	The promising role of nivolumab in renal cell cancers. Cancer Biology and Therapy, 2016, 17, 123-124.	1.5	7
66	Carcinomas of the Renal Pelvis, Ureters, and Urinary Bladder Share a Carcinogenic Field as Revealed in Epidemiological Analysis of Tumor Registry Data. Clinical Genitourinary Cancer, 2019, 17, 436-442.	0.9	7
67	Frontline immunotherapy treatment with nivolumab and ipilimumab in metastatic renal cell cancer: a new standard of care. Cancer Biology and Therapy, 2019, 20, 6-7.	1.5	7
68	The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. Urologic Clinics of North America, 2020, 47, 457-467.	0.8	7
69	The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer. Asian Journal of Andrology, 2021, 23, 1.	0.8	7
70	Reimbursement Policy and Androgen-Deprivation Therapy for Prostate Cancer. New England Journal of Medicine, 2011, 364, 579-580.	13.9	6
71	Use of Denosumab for Renal Cell Carcinoma-Associated Malignant Hypercalcemia: A Case Report and Review of the Literature. Clinical Genitourinary Cancer, 2013, 11, e24-e26.	0.9	6
72	Advanced prostate cancer – patient survival and potential impact of enzalutamide and other emerging therapies. Therapeutics and Clinical Risk Management, 2014, 10, 651.	0.9	6

#	Article	IF	Citations
73	Maintenance avelumab for metastatic urothelial cancer: a new standard of care. Cancer Biology and Therapy, 2020, 21, 1095-1096.	1.5	6
74	Pembrolizumab use in bladder cancer: a tale of two trials. Nature Reviews Urology, 2021, 18, 577-578.	1.9	6
75	Carcinomas of the renal pelvis, ureters, and urinary bladder arise by similar carcinogenic pathways: A pathoepidemiological analysis.. Journal of Clinical Oncology, 2019, 37, 403-403.	0.8	6
76	Active Surveillance for Prostate Cancer: Has the Time Finally Come?. Journal of Clinical Oncology, 2010, 28, e265-e266.	0.8	5
77	Enzalutamide (formerly MDV3100) as a new therapeutic option for men with metastatic castration-resistant prostate cancer. Asian Journal of Andrology, 2012, 14, 805-806.	0.8	5
78	Ipilimumab. Cancer Biology and Therapy, 2014, 15, 1299-1300.	1.5	5
79	New Developments and Challenges in Rare Genitourinary Tumors: Non-Urothelial Bladder Cancers and Squamous Cell Cancers of the Penis. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 330-336.	1.8	5
80	New Developments and Challenges in Rare Genitourinary Tumors: Non-Urothelial Bladder Cancers and Squamous Cell Cancers of the Penis. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 330-336.	1.8	5
81	Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Are We Asking the Right Questions?. Journal of Clinical Oncology, 2014, 32, 4169-4170.	0.8	4
82	Advances in systemic therapies for metastatic castration-resistant prostate cancer. Future Oncology, 2014, 10, 2213-2226.	1.1	4
83	Osteonecrosis of the jaw (ONJ) in androgen-independent prostate cancer (AIPC) patients receiving ATTP (bevacizumab, docetaxel, thalidomide, and prednisone). Journal of Clinical Oncology, 2007, 25, 19594-19594.	0.8	4
84	Differences in survival among non-urothelial bladder cancers: Analyses of SEER 1988-2008.. Journal of Clinical Oncology, 2018, 36, 425-425.	0.8	4
85	Darolutamide for treatment of castration-resistant prostate cancer. Drugs of Today, 2020, 56, 185.	0.7	4
86	Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer. Asian Journal of Andrology, 2020, 22, 76.	0.8	4
87	Further analysis of the survival benefit of clodronate. Cancer Biology and Therapy, 2009, 8, 2219-2220.	1.5	3
88	About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?. Annals of Oncology, 2010, 21, 183-184.	0.6	3
89	2508 Three-arm phase II randomized trial of docetaxel monotherapy or combined with ramucirumab or icrucumab in second-line locally advanced or metastatic urothelial carcinoma. European Journal of Cancer, 2015, 51, S476.	1.3	3
90	Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer. Clinical Medicine Insights: Oncology, 2016, 10s1, CMO.Ss30751.	0.6	3

#	Article	IF	Citations
91	Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives. Cancer Management and Research, 2017, Volume 9, 299-306.	0.9	3
92	Formidable Scenarios in Urothelial and Variant Cancers of the Urinary Tract. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 262-275.	1.8	3
93	Treatment in hormone-sensitive metastatic prostate cancer: factors to consider when personalizing therapy. Expert Review of Anticancer Therapy, 2020, 20, 483-490.	1.1	3
94	Plasmacytoid Variant of Urothelial Carcinoma: Poor Prognostic Variant with High Expression of CDH1 Mutation. Uro, 2021, 1, 23-29.	0.3	3
95	Darolutamide (DARO) tolerability from extended follow up and treatment response in the phase 3 ARAMIS trial.. Journal of Clinical Oncology, 2021, 39, 5079-5079.	0.8	3
96	Molecular profiling of aggressive variant urothelial carcinoma.. Journal of Clinical Oncology, 2019, 37, 378-378.	0.8	3
97	The Utility of Chemotherapy in the Treatment of Metastatic Prostate Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2016, 16, 1166-1171.	0.9	3
98	The path forward in prostate cancer therapeutics. Asian Journal of Andrology, 2018, 20, 213.	0.8	3
99	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. Nature Communications, 2022, 13, 1878.	5.8	3
100	Editorial [Hot topic: Prostate Cancer Therapy (Guest Editors: N. Sharifi and J.B. Aragon-Ching)]. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 1039-1039.	0.9	2
101	Cytotoxic Compounds in the Treatment of Castration-Resistant Prostate Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 1040-1045.	0.9	2
102	Is there an optimal treatment sequencing strategy for metastatic castration-resistant prostate cancer?. Future Oncology, 2013, 9, 619-622.	1.1	2
103	Further analysis of PREVAIL: Enzalutamide use in chemotherapy-naÃ¯ve men with metastatic castration-resistant prostate cancer. Asian Journal of Andrology, 2014, 16, 803.	0.8	2
104	Mucinous Signet-Ring Urachal Carcinoma of the Bladder: Case Report and Review of the Literature. Clinical Genitourinary Cancer, 2017, 15, e889-e891.	0.9	2
105	Promises and Pitfalls of Primary Local Treatment in Metastatic Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 914-914.	0.8	2
106	Adjuvant Chemotherapy for High-Risk Localized Prostate Cancer: Time for Change or Need More Time to Change?. Journal of Clinical Oncology, 2019, 37, 2296-2297.	0.8	2
107	The Clinical Utility of Bevacizumab. , 2008, , 375-385.		2
108	Comparative analyses of trends and survival in patients with urothelial versus nonurothelial bladder carcinoma: National Cancer Database (NCDB) analysis.. Journal of Clinical Oncology, 2019, 37, 402-402.	0.8	2

#	Article	IF	Citations
109	The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer. Asian Journal of Andrology, 2016, 18, 592.	0.8	2
110	Characterization of differences between prostate cancer (PCa) patients presenting as de novo versus primary progressive metastatic disease.. Journal of Clinical Oncology, 2015, 33, 285-285.	0.8	2
111	Non-urothelial bladder cancer: Genomic alterations and patient outcomes.. Journal of Clinical Oncology, 2019, 37, 399-399.	0.8	2
112	Cardiovascular Disease With Androgen Deprivation: The (forgotten) Role of Testosterone. Journal of Clinical Oncology, 2009, 27, e261-e261.	0.8	1
113	Editorial [Hot Topic: Multidrug Resistance: Genes, Polymorphisms, Biologic Effects, Reversal and Treatment in Cancer Chemotherapy (Guest Editor: Jeanny B. Aragon-Ching)]. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 582-582.	0.9	1
114	The use of 5-alpha-reductase inhibitors for the prevention of prostate cancer. Cancer Biology and Therapy, 2010, 10, 11-12.	1.5	1
115	Mechanisms of Drug Resistance to Vascular Endothelial Growth Factor (VEGF) Inhibitors. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 593-600.	0.9	1
116	Hematuria in sickle cell trait: the importance of ruling out occult cancer. Annals of Hematology, 2012, 91, 137-138.	0.8	1
117	Targeting the androgen receptor in metastatic castration-resistant prostate cancer. Future Oncology, 2014, 10, 329-332.	1.1	1
118	Drug therapies for metastatic castration-resistant prostate cancer. Future Oncology, 2015, 11, 2395-2403.	1.1	1
119	The Emerging Role of Combination Angiogenesis Inhibitors and Immune Checkpoint Inhibitors in the Treatment of Metastatic Renal Cell Cancer. Kidney Cancer, 2019, 3, 81-91.	0.2	1
120	Life under the CABOSUN: Cabozantinib improves qualityâ€adjusted survival in comparison with sunitinib. Cancer, 2020, 126, 5210-5212.	2.0	1
121	Characterization of Brain Metastases in Urothelial Cancers. Clinical Genitourinary Cancer, 2020, 18, e679-e683.	0.9	1
122	Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies. Oncoscience, 2021, 8, 40-45.	0.9	1
123	Implications for chemoprevention of prostate cancer with intake of cruciferous vegetables. Asian Journal of Andrology, 2011, 13, 357-358.	0.8	1
124	Circulating tumor cells (CTCs) in biochemical recurrence (BR) of prostate cancer: Final results.. Journal of Clinical Oncology, 2013, 31, 179-179.	0.8	1
125	A phase I/II trial of ketoconazole + calcitriol [1,25(OH)2D3] in castration-resistant prostate cancer.. Journal of Clinical Oncology, 2016, 34, 5065-5065.	0.8	1
126	Retrospective review of clear cell and non-clear cell renal carcinomas: Characteristics and course in the pre-TKI (tyrosine kinase inhibitor) and post-TKI era.. Journal of Clinical Oncology, 2017, 35, e16052-e16052.	0.8	1

#	Article	IF	Citations
127	Treatment utilization patterns for prostate cancer (PCa): An analysis from the National Cancer Database (NCDB).. Journal of Clinical Oncology, 2017, 35, 99-99.	0.8	1
128	Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer. Asian Journal of Andrology, 2019, 21, 107.	0.8	1
129	Investigational Angiogenesis Inhibitors. , 2010, , 225-232.		1
130	Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled. Current Molecular Pharmacology, 2013, 5, 382-391.	0.7	1
131	Contemporary treatment and survival differences in patients with urothelial versus nonurothelial bladder and upper tract carcinomas: Analyses from the National Cancer Database (NCDB).. Journal of Clinical Oncology, 2022, 40, 463-463.	0.8	1
132	Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer. BJU International, 2007, 100, 1245-1248.	1.3	0
133	Reply. Clinical Cancer Research, 2009, 15, 7749-7749.	3.2	0
134	New Pharmacotherapies in the Treatment of Advanced Prostate Cancer. Clinical Medicine Insights Urology, 2010, 4, CMU.S5075.	0.4	0
135	Circulating Tumor Cells. , 2014, 19, 229-233.		0
136	Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED. Asian Journal of Andrology, 2016, 18, 444.	0.8	0
137	Key Difficulties Associated with Cancer Biology. Clinical Medicine Insights: Oncology, 2016, 10s1, CMO.S41271.	0.6	0
138	The emerging role of checkpoint inhibitors for rare genitourinary cancers. Nature Reviews Urology, 2021, 18, 133-134.	1.9	0
139	Comparative analyses of survival differences in patients with urothelial versus non-urothelial upper tract carcinomas: Results from the National Cancer Database (NCDB).. Journal of Clinical Oncology, 2021, 39, e16582-e16582.	0.8	0
140	MP41-13â€ƒAVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: ANALYSIS OF CLINICAL AND GENOMIC SUBGROUPS FROM THE JAVELIN BLADDER 100 TRIAL. Journal of Urology, 2021, 206, .	0.2	0
141	PD40-11â€ƒCLINICAL ACTIVITY OF NIVOLUMAB IN ADVANCED HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER (HLRCC)-ASSOCIATED KIDNEY CANCER. Journal of Urology, 2021, 206, .	0.2	0
142	Exploratory covariate analysis for phase II clinical trial of sorafenib (S) in metastatic castrate-resistant prostate cancer (mCRPC). Journal of Clinical Oncology, 2008, 26, 14690-14690.	0.8	0
143	Circulating tumor cells (CTCs) as a predictor of metastatic disease in patients with biochemical recurrence (BR) of prostate cancer with equivocal scan results.. Journal of Clinical Oncology, 2012, 30, 239-239.	0.8	0
144	Pilot study assessing distressors affecting patients with cancer using the distress screening tool.. Journal of Clinical Oncology, 2015, 33, 68-68.	0.8	0

#	Article	IF	Citations
145	Effects of PSA screening guidelines on trends of diagnosis and treatment for prostate cancer: Analysis from the National Cancer Data Base (NCDB).. Journal of Clinical Oncology, 2016, 34, 74-74.	0.8	0
146	Incidence and characterization of pure non-urothelial bladder and upper tract cancers: A 10-year review.. Journal of Clinical Oncology, 2016, 34, 414-414.	0.8	0
147	Survival outcomes for de novo versus primary progressive metastatic prostate cancer.. Journal of Clinical Oncology, 2017, 35, 258-258.	0.8	0
148	Survival outcomes and patterns of utilization of cytoreductive nephrectomy in the tyrosine kinase inhibitors (TKI)-era in metastatic clear cell renal cell carcinoma (ccRCC) and non-clear cell renal cell carcinoma (nccRCC): Analyses from the National Cancer Database (NCDB).. Journal of Clinical Oncology, 2017, 35, e16068-e16068.	0.8	0
149	Molecular characterization of brain metastases in patients with metastatic urothelial cancer.. Journal of Clinical Oncology, 2018, 36, 509-509.	0.8	0
150	Pilot Study Assessing Distressors Affecting Patients with Cancer Using the Distress Thermometer Screening Tool. Hematology & Medical Oncology, 2020, 5, .	0.1	0
151	Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS metastases: the Road less Travelled. Current Molecular Pharmacology, 2013, , .	0.7	0
152	Rapidly evolving first-line therapy using checkpoint inhibitors in metastatic renal cell cancer. Future Medicinal Chemistry, 2022, , .	1.1	0